ES2189750T3 - Formulacion de propofol que contiene tris. - Google Patents

Formulacion de propofol que contiene tris.

Info

Publication number
ES2189750T3
ES2189750T3 ES00918250T ES00918250T ES2189750T3 ES 2189750 T3 ES2189750 T3 ES 2189750T3 ES 00918250 T ES00918250 T ES 00918250T ES 00918250 T ES00918250 T ES 00918250T ES 2189750 T3 ES2189750 T3 ES 2189750T3
Authority
ES
Spain
Prior art keywords
formulation
containing tris
propofol containing
propofol
signficant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00918250T
Other languages
English (en)
Inventor
Mary Mathew George
Pui-Ho Yuen
Martin A Joyce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of ES2189750T3 publication Critical patent/ES2189750T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición farmacéutica estéril para administración parenteral, que comprende una emulsión de aceite en agua que comprende propofol en un disolvente inmiscible en agua y una cantidad de trometamina, siendo dichas cantidades suficientes para prevenir un aumento no superior a diez veces en el crecimiento de microorganismos durante al menos veinticuatro horas tras la contaminación extrínseca adventicia.
ES00918250T 1999-03-24 2000-03-23 Formulacion de propofol que contiene tris. Expired - Lifetime ES2189750T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/275,145 US6177477B1 (en) 1999-03-24 1999-03-24 Propofol formulation containing TRIS

Publications (1)

Publication Number Publication Date
ES2189750T3 true ES2189750T3 (es) 2003-07-16

Family

ID=23051046

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00918250T Expired - Lifetime ES2189750T3 (es) 1999-03-24 2000-03-23 Formulacion de propofol que contiene tris.

Country Status (10)

Country Link
US (1) US6177477B1 (es)
EP (1) EP1163007B1 (es)
AT (1) ATE231003T1 (es)
AU (1) AU3909400A (es)
BR (1) BR0009286A (es)
CA (1) CA2367093A1 (es)
DE (1) DE60001223T2 (es)
DK (1) DK1163007T3 (es)
ES (1) ES2189750T3 (es)
WO (1) WO2000056364A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DE69912441T2 (de) 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
EP1292282A2 (en) 2000-06-16 2003-03-19 RTP Pharma Inc. Improved injectable dispersions of propofol
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
NZ533536A (en) * 2001-12-28 2006-11-30 Mgi Gp Inc Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol such as O-phosphonooxymethyl propofol
NZ534012A (en) * 2002-01-25 2006-12-22 Theravance Inc Substituted phenylacetic acid ester compounds as short-acting sedative hypnotic agents for anesthesia and sedation
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
KR100459025B1 (ko) * 2002-05-02 2004-12-03 (주) 에프디엘 프로포폴을 함유하는 신규한 주사제용 조성물
AU2003222491A1 (en) * 2002-05-02 2003-12-31 Fdl, Inc. Novel parenteral composition comprising propofol
AU2003286725B2 (en) * 2002-10-29 2007-07-12 Transform Pharmaceuticals, Inc. Propofol with cysteine
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
DE602004023509D1 (de) * 2003-07-23 2009-11-19 Theravance Inc Pharmazeutische zusammensetzungen eines kurzwirkenden sedativen hypnosemittels
US8546453B2 (en) * 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
EP1850829A4 (en) * 2005-02-03 2012-12-26 Taro Pharmaceuticals Usa Inc NEW PROPOLFOL COMPOSITION WITH ASCORBIC ACID OR PHARMACEUTICALLY USEFUL SALTS
CN100358513C (zh) * 2005-04-07 2008-01-02 常州市第四制药厂有限公司 一种丙泊酚注射液的制备工艺
US20090131538A1 (en) * 2005-05-27 2009-05-21 Taro Pharmaceuticals North America, Inc. c/o Taro Pharmaceuticals U.S.A., Inc. Novel propofol composition comprising a pharmaceutically acceptable salt of formaldehyde sulfoxylate
EP3527202A1 (en) * 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
LT3311805T (lt) * 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
US9132090B2 (en) 2009-01-13 2015-09-15 Chetan Majmudar Propofol based anesthetic with preservative
PL2547323T3 (pl) 2010-03-17 2016-07-29 Novaliq Gmbh Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
ES2711760T3 (es) * 2011-01-04 2019-05-07 Novaliq Gmbh Emulsiones de aceite/agua que comprenden alcanos semifluorados
DK2714010T3 (en) 2011-05-25 2017-06-12 Novaliq Gmbh TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORED ALKANES
JP6023181B2 (ja) 2011-05-25 2016-11-09 ノバリック ゲーエムベーハー 爪に投与するための医薬組成物
KR101989648B1 (ko) 2012-01-23 2019-06-14 노바리크 게엠베하 부분불소화 알칸에 기초한 안정화된 단백질 조성물
WO2013172999A1 (en) 2012-05-16 2013-11-21 Mewa Singh Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
WO2014033751A2 (en) * 2012-08-16 2014-03-06 Emcure Pharmaceuticals Limited Pharmaceutical composition of propofol
CN113679699B (zh) 2012-09-12 2022-10-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
AU2013314303B2 (en) 2012-09-12 2018-01-18 Novaliq Gmbh Semifluorinated alkane compositions
PT3024484T (pt) 2013-07-23 2018-10-24 Novaliq Gmbh Composições de anticorpo estabilizadas
US11219606B2 (en) * 2013-10-11 2022-01-11 University Of Florida Research Foundation, Inc. Method of manufacturing stable emulsions and compositions containing the same
CN106714787A (zh) * 2014-09-25 2017-05-24 富士胶片株式会社 含丙泊酚的水包油型乳液组合物及其制造方法
US10821087B2 (en) 2015-07-24 2020-11-03 Neon Laboratories Limited Stabilized injectable emulsion of Propofol and Ketamine
WO2017031261A1 (en) 2015-08-20 2017-02-23 Mewa Singh Polyphenolic polymer to make water-insoluble molecules become water-soluble
US11154513B2 (en) 2015-09-30 2021-10-26 Novaliq Gmbh Semifluorinated compounds
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
PT3442480T (pt) 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
CA3036297C (en) 2016-09-22 2023-09-05 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
WO2018055101A1 (en) 2016-09-23 2018-03-29 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
EP4374851B1 (en) 2016-12-23 2026-04-15 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
KR20200128407A (ko) 2018-03-02 2020-11-12 노바리크 게엠베하 네비볼롤을 포함하는 약제학적 조성물
SG11202007860XA (en) 2018-03-28 2020-09-29 Novaliq Gmbh Pharmaceutical composition comprising timolol
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4060639A (en) * 1976-05-14 1977-11-29 Merck & Co., Inc. Broad spectrum antibacterial compositions containing tris-(hydroxymethyl)-aminoethane and dicycloaliphatic-alkyl polyamines
DE4028957C2 (de) * 1990-09-12 1994-05-11 Oliver Bock Therapeutikum für den Mundbereich
US5504113A (en) * 1994-03-02 1996-04-02 Allergan, Inc. Enhancement of benzalkonium chloride preservative activity in formulations containing an incompatible drug
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US5633240A (en) * 1994-09-01 1997-05-27 Academic Pharmaceuticals Parenteral solutions containing metolazone
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
CH692322A5 (it) * 1997-05-26 2002-05-15 Westy Ag Formulazione iniettabile limpida di Propofol.
US5962536A (en) * 1998-07-31 1999-10-05 Komer; Gene Injectable propofol formulations
US6028108A (en) * 1998-10-22 2000-02-22 America Home Products Corporation Propofol composition comprising pentetate

Also Published As

Publication number Publication date
ATE231003T1 (de) 2003-02-15
US6177477B1 (en) 2001-01-23
CA2367093A1 (en) 2000-09-28
DE60001223T2 (de) 2004-01-22
DK1163007T3 (da) 2003-04-22
BR0009286A (pt) 2002-01-22
WO2000056364A1 (en) 2000-09-28
EP1163007B1 (en) 2003-01-15
AU3909400A (en) 2000-10-09
DE60001223D1 (de) 2003-02-20
EP1163007A1 (en) 2001-12-19

Similar Documents

Publication Publication Date Title
ES2189750T3 (es) Formulacion de propofol que contiene tris.
NO20011967D0 (no) Propofolblandinger omfattende pentetrat
CA2319810A1 (en) Propofol composition containing sulfite
EP1238677A3 (en) Parenteral fat emulsions comprising edetate as preservative
MY125921A (en) Compositions containing organic compounds
SE7703592L (sv) Anthelmintikum
AU589378B2 (en) Pharmaceutical compositions containing inositol triphosphates
ES2060031T3 (es) Formulacion que contiene un derivado de imidazo(4,5-c)quinoleina.
EP0661060A3 (de) Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung.
MX9301032A (es) Compuestos farmaceuticos y procedimento para su preparacion
DE60133555D1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
NO964433L (no) Farmasöytiske preparater på basis av derivater av taxanklassen
MX9204637A (es) Nuevos derivados de pirazina y procedimiento para su preparacion.
DE3866408D1 (de) Selbstklebende vorrichtung zur transdermalen verabreichung eines wirkstoffs.
WO2004100935A3 (en) Propofol formulation containing reduced oil and surfactants
ES2179667T3 (es) Nuevas formulaciones inyectables que contienen ramoplanina.
ATE90095T1 (de) Optisch aktive produkte von 20,21dinoreburnamenin-derivaten,verfahren zur herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammenstellungen.
WO2007000662A3 (en) Novel propofol composition comprising ascorbic acid or pharmaceutically acceptable salts thereof
ES2059594T3 (es) Peptidos con actividad inhibidora de sistemas enzimaticos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
BRPI9908132B8 (pt) composição farmacêutica líquida para administração oral
AR004223A1 (es) Composiciones para inhibir la agregacion de plaquetas y el uso de las mismas en la manufactura de un medicamento.
UA33167A (uk) Комбінована мазь для лікування ран "мазь фенітол"